The Filing Desk

Akso Health Group

AHG · Nasdaq · Health Care · Financials, fiscal 2017 to 2026

AHG · Last close · November 19, 2026
$1.28

Akso Health Group's revenue fell 6.4% to $14 million in fiscal 2026. Its operating margin was −149.7%, up from −1,125.4% a year earlier. Free cash flow was −$13 million, against $1 million a year earlier. The diluted share count rose 153.5%.

Akso Health Group Latest fiscal year ended March 31, 2026 20-F filed July 23, 2026 · 0001213900-26-080868 Updated
Revenue
$14M
6.4%
Operating margin
−149.7%
975.7 pts
Net income
−$19M
 
Free cash flow
−$13M
$1M a year earlier
Return on equity
−9.8%
70.2 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. Akso Health Group is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model. Diluted earnings per share for fiscal 2024 to 2025 is left blank: the SEC's structured data gives it the opposite sign from net income per share.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2017 to 2019, earnings per share fell 29.3% a year and net income 20.0% a year, as new shares raised the share count by 25% and diluted each share's earnings. Akso Health Group then lost money in fiscal 2020, 2021, 2022, 2023, 2024, 2025 and 2026.

Diluted earnings per share
US$ per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments188851760
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−4.0x−42.4x−77.4x——
Current ratio1.2x1.8x39.5x14.2x21.8x
Quick ratio1.1x1.6x39.5x14.2x21.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, billions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25FY26
Piotroski F-score———
Rule of 40—519.0%−98.9%
Altman Z''44.9610.5823.59
Accruals ratio−13.3%−76.3%−2.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25FY26
Net income is positiveFailFailFail
Cash from operations is positivePassPassFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin roseFailFailPass
Revenue rose relative to assetsFailFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Akso Health Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Akso Health GroupFY26−6.4%−149.7%−92.5%———
DataMeds AIFY2528.7%−401.7%—−369.5%—3Compare
Quanome TechnologiesFY26111.8%−174.2%−54.5%———Compare
Cosmos HealthFY2519.9%−25.6%−13.0%−53.0%—5Compare
Accendra HealthFY253.1%1.0%−10.6%1.2%7.3x2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue2310747261321514
Revenue growth—368.0%−96.5%87.1%−74.6%241.9%119.7%−81.7%512.1%−6.4%
Gross profit23107−472110−0−0
Research and development230000————
Operating income1076−7−48−4−3−14−9−166−21
Net income9666−71−35−17−1−10−135−19
Diluted EPS (US$)0.201.370.10−1.46−0.71−0.28−0.02——0.01
Diluted shares (millions)424853494960691428552,168
Cash flow
Cash from operations888−2−5810−9−311−13
Capital expenditure0000—0——00
Free cash flow887−2−58—−9——1−13
Dividends paid00200000000
Share buybacks0013000000
Acquisitions000000056940
Stock-based compensation027000————
Balance sheet at fiscal year end
Cash and short-term investments1913357715188851760
Debt incl. finance leases——2020——————
Total assets2816417380326320142215190
Total liabilities52447321450124169
Shareholders' equity241401264817129138199181
Margins and ratios
Gross margin100.0%100.0%−100.2%100.0%100.0%10.1%9.6%5.1%−1.9%−0.1%
Operating margin43.2%70.7%−194.6%−695.7%−241.7%−54.3%−108.2%−357.8%−1,125.4%−149.7%
Net margin37.4%61.0%149.7%−1,029.7%−1,984.5%−280.9%−10.3%−391.8%−913.4%−135.0%
Free cash flow margin34.5%81.4%−47.0%−845.8%—−143.9%——6.9%−92.5%
Rule of 40 (growth + FCF margin)—449.3%−143.6%−758.6%—98.0%——519.0%−98.9%
Return on capital———−50.5%——————
Return on equity—80.1%4.2%−81.5%−106.5%−114.0%−12.9%−12.9%−80.0%−9.8%
Return on assets—68.1%3.3%−56.1%−62.1%−35.7%−3.3%−11.6%−75.6%−9.2%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Akso Health Group's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Akso Health Group.